Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma

Center for International Blood and Marrow Transplant Research Lymphoma Working Committee

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Assessment with 18F-fluorodeoxy glucose (FDG)-positron emission tomography (PET) before hematopoietic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with chemotherapy-sensitive non-Hodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We analyzed 336 patients; median age was 55 years and 60% were males. Follicular lymphoma (n = 104) was more common than large cell (n = 85), mantle cell (n = 69), and mature natural killer or T cell lymphoma (n = 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159 were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival (PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40% versus 26%; P = .007; 43% versus 47%; P = .47; and 58% versus 60%; P = .73, respectively. On multivariate analysis, a positive pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86; P = .001) but was not associated with increased mortality (RR, 1.29, 95% confidence interval [CI], .96 to 1.7; P = .08), therapy failure (RR, 1.32; 95% CI, .95 to 1.84; P = .10), or nonrelapse mortality (RR, .75; 95% CI, .48 to 1.18; P = .22). PET status conferred no influence on graft-versus-host disease. A positive PET scan before HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful allograft. PET status does not appear to predict survival after allogeneic HCT for NHL.

Original languageEnglish (US)
Pages (from-to)1605-1611
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume21
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Cell Transplantation
Positron-Emission Tomography
Non-Hodgkin's Lymphoma
Glucose
Odds Ratio
Confidence Intervals
Recurrence
Transplantation
Unrelated Donors
Follicular Lymphoma
Natural Killer T-Cells
Survival
Mortality
T-Cell Lymphoma
Graft vs Host Disease
Disease-Free Survival
Allografts
Registries
Lymphoma
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

@article{27f6c8a2ba7c45bc8d04351bebcf8780,
title = "Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma",
abstract = "Assessment with 18F-fluorodeoxy glucose (FDG)-positron emission tomography (PET) before hematopoietic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with chemotherapy-sensitive non-Hodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We analyzed 336 patients; median age was 55 years and 60{\%} were males. Follicular lymphoma (n = 104) was more common than large cell (n = 85), mantle cell (n = 69), and mature natural killer or T cell lymphoma (n = 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159 were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival (PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40{\%} versus 26{\%}; P = .007; 43{\%} versus 47{\%}; P = .47; and 58{\%} versus 60{\%}; P = .73, respectively. On multivariate analysis, a positive pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86; P = .001) but was not associated with increased mortality (RR, 1.29, 95{\%} confidence interval [CI], .96 to 1.7; P = .08), therapy failure (RR, 1.32; 95{\%} CI, .95 to 1.84; P = .10), or nonrelapse mortality (RR, .75; 95{\%} CI, .48 to 1.18; P = .22). PET status conferred no influence on graft-versus-host disease. A positive PET scan before HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful allograft. PET status does not appear to predict survival after allogeneic HCT for NHL.",
author = "{Center for International Blood and Marrow Transplant Research Lymphoma Working Committee} and Veronika Bachanova and Burns, {Linda J.} and Ahn, {Kwang Woo} and Laport, {Ginna G.} and G{\"o}rg{\"u}n Akpek and Kharfan-Dabaja, {Mohamed A.} and Taiga Nishihori and Edward Agura and Philippe Armand and Jaglowski, {Samantha M.} and Cairo, {Mitchell S.} and Cashen, {Amanda F.} and Cohen, {Jonathon B.} and Anita D'Souza and Freytes, {C{\'e}sar O.} and Gale, {Robert Peter} and Siddhartha Ganguly and Nilanjan Ghosh and Holmberg, {Leona A.} and Inwards, {David J.} and Kanate, {Abraham S.} and Lazarus, {Hillard M.} and Malone, {Adriana K.} and Reinhold Munker and Alberto Mussetti and Maxim Norkin and Prestidge, {Tim D.} and Rowe, {Jacob M.} and Prakash Satwani and Tanya Siddiqi and Stiff, {Patrick J.} and William, {Basem M.} and Baldeep Wirk and Maloney, {David G.} and Smith, {Sonali M.} and Sureda, {Anna M.} and Jeanette Carreras and Mehdi Hamadani",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.bbmt.2015.05.007",
language = "English (US)",
volume = "21",
pages = "1605--1611",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "9",

}

Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. / Center for International Blood and Marrow Transplant Research Lymphoma Working Committee.

In: Biology of Blood and Marrow Transplantation, Vol. 21, No. 9, 01.09.2015, p. 1605-1611.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma

AU - Center for International Blood and Marrow Transplant Research Lymphoma Working Committee

AU - Bachanova, Veronika

AU - Burns, Linda J.

AU - Ahn, Kwang Woo

AU - Laport, Ginna G.

AU - Akpek, Görgün

AU - Kharfan-Dabaja, Mohamed A.

AU - Nishihori, Taiga

AU - Agura, Edward

AU - Armand, Philippe

AU - Jaglowski, Samantha M.

AU - Cairo, Mitchell S.

AU - Cashen, Amanda F.

AU - Cohen, Jonathon B.

AU - D'Souza, Anita

AU - Freytes, César O.

AU - Gale, Robert Peter

AU - Ganguly, Siddhartha

AU - Ghosh, Nilanjan

AU - Holmberg, Leona A.

AU - Inwards, David J.

AU - Kanate, Abraham S.

AU - Lazarus, Hillard M.

AU - Malone, Adriana K.

AU - Munker, Reinhold

AU - Mussetti, Alberto

AU - Norkin, Maxim

AU - Prestidge, Tim D.

AU - Rowe, Jacob M.

AU - Satwani, Prakash

AU - Siddiqi, Tanya

AU - Stiff, Patrick J.

AU - William, Basem M.

AU - Wirk, Baldeep

AU - Maloney, David G.

AU - Smith, Sonali M.

AU - Sureda, Anna M.

AU - Carreras, Jeanette

AU - Hamadani, Mehdi

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Assessment with 18F-fluorodeoxy glucose (FDG)-positron emission tomography (PET) before hematopoietic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with chemotherapy-sensitive non-Hodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We analyzed 336 patients; median age was 55 years and 60% were males. Follicular lymphoma (n = 104) was more common than large cell (n = 85), mantle cell (n = 69), and mature natural killer or T cell lymphoma (n = 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159 were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival (PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40% versus 26%; P = .007; 43% versus 47%; P = .47; and 58% versus 60%; P = .73, respectively. On multivariate analysis, a positive pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86; P = .001) but was not associated with increased mortality (RR, 1.29, 95% confidence interval [CI], .96 to 1.7; P = .08), therapy failure (RR, 1.32; 95% CI, .95 to 1.84; P = .10), or nonrelapse mortality (RR, .75; 95% CI, .48 to 1.18; P = .22). PET status conferred no influence on graft-versus-host disease. A positive PET scan before HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful allograft. PET status does not appear to predict survival after allogeneic HCT for NHL.

AB - Assessment with 18F-fluorodeoxy glucose (FDG)-positron emission tomography (PET) before hematopoietic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with chemotherapy-sensitive non-Hodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We analyzed 336 patients; median age was 55 years and 60% were males. Follicular lymphoma (n = 104) was more common than large cell (n = 85), mantle cell (n = 69), and mature natural killer or T cell lymphoma (n = 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159 were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival (PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40% versus 26%; P = .007; 43% versus 47%; P = .47; and 58% versus 60%; P = .73, respectively. On multivariate analysis, a positive pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86; P = .001) but was not associated with increased mortality (RR, 1.29, 95% confidence interval [CI], .96 to 1.7; P = .08), therapy failure (RR, 1.32; 95% CI, .95 to 1.84; P = .10), or nonrelapse mortality (RR, .75; 95% CI, .48 to 1.18; P = .22). PET status conferred no influence on graft-versus-host disease. A positive PET scan before HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful allograft. PET status does not appear to predict survival after allogeneic HCT for NHL.

UR - http://www.scopus.com/inward/record.url?scp=84938993122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938993122&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2015.05.007

DO - 10.1016/j.bbmt.2015.05.007

M3 - Article

C2 - 25983043

AN - SCOPUS:84938993122

VL - 21

SP - 1605

EP - 1611

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 9

ER -